Clinical trial · Observational
Circulating Tumor Extracellular Vesicles for Non-Invasive Monitoring of Metastatic Colorectal Cancer
Circulating Tumor Extracellular Vesicles As Novel Non-invasive Biomarkers to Monitor Metastatic Colorectal Cancer Transcriptomic and Proteomic Evolution
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Metastatic colorectal cancer (mCRC) remains a major clinical challenge due to heterogeneous treatment responses and the development of therapeutic resistance. Current tissue-based molecular profiling is limited by invasiveness and the inability to enable longitudinal monitoring. Extracellular vesicles (EVs) represent a promising source of non-invasive biomarkers, carrying stable RNA and proteins reflective of tumor biology. This study aims to identify and validate EV-derived transcriptomic and proteomic biomarkers to monitor disease evolution, predict treatment response, and support personalized management of patients with mCRC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Retrospective cohort
- description
- The retrospective cohort will include 160 patients with metastatic colorectal cancer (mCRC) who have previously received first-line systemic therapy (chemotherapy with or without targeted biological agents). Biological samples and corresponding clinical data, collected as part of routine clinical practice between 2017 and 2025, will be retrospectively analyzed.
- label
- Prospective cohort
- description
- The prospective cohort will include 130 treatment-naïve patients with metastatic colorectal cancer (mCRC) who will be prospectively enrolled at the start of first-line systemic therapy for longitudinal collection of biological samples and clinical data.
- interventionNames
- Other: Blood sample
Primary outcomes (1)
- measure
- Identification and Validation of Extracellular Vesicle-Derived Biomarkers in Metastatic Colorectal Cancer
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Retrospective Cohort Inclusion Criteria: * Age ≥ 18 years; * Histologically confirmed diagnosis of colorectal adenocarcinoma; * Radiological evidence of metastatic or locally advanced unresectable disease; * First-line treatment for metastatic disease already completed or ongoing according to standard clinical practice; * Availability of stored biological samples collected at least at one of the protocol-defined time points (baseline, post-treatment, disease progression); * Informed consent acquisition will be performed in accordance with Article 110-bis of the Italian Privacy Code. Retrospective Cohort Exclusion Criteria: * Absence of suitable biological samples or samples unsuitable for molecular analyses; * Incomplete clinical data preventing the performance of the planned analyses; * Insufficient quality of stored biological samples for the assessment of EV-RNA and EV-PROT analyses. Prospective Cohort Inclusion Criteria: * Age ≥ 18 years; * Histologically confirmed diagnosis of colorectal adenocarcinoma; * Radiological evidence of unresectable metastatic disease; * Patients not previously treated for metastatic disease (prior completed adjuvant/neoadjuvant therapy is allowed if completed ≥ 6 months before study enrollment); * Indication for first-line treatment with chemotherapy ± biological therapy according to standard clinical practice; * Ability to understand the study procedures and provide written informed consent. Prospective Cohort Exclusion Criteria: * Previous systemic treatment for metastatic disease (except prior adjuvant/neoadjuvant therapy as specified above); * Ongoing pregnancy or breastfeeding; * Legal incapacity or limitation in the ability to provide informed consent.
References
Publications (0)
Data not yet available